Key clinical point: Compared with obinutuzumab alone, obinutuzumab combined with zanubrutinib significantly improved outcomes in patients with relapsed or refractory follicular lymphoma (FL) without causing safety concerns.
Major finding: At a median follow-up of 20.2 months, patients receiving zanubrutinib + obinutuzumab vs single-agent obinutuzumab had a significantly higher overall response rate (69% vs 46%; P = .001) and longer median progression-free survival (28.0 vs 10.4 months; hazard ratio 0.50; P < .001). The safety profile of zanubrutinib + obinutuzumab was consistent with the known safety profile of the individual drugs.
Study details: Findings are from the phase 2 ROSEWOOD study including 217 patients with FL who were refractory to or had relapsed after ≥ 2 prior systemic treatments, including an anti-CD20 antibody and alkylating agent, and were randomly assigned to receive zanubrutinib + obinutuzumab (n = 145) or Obinutuzumab alone (n = 72).
Disclosures: This study was sponsored by BeiGene. No information on conflicts of interest was provided.
Source: Zinzani PL et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol. 2023 (Jul 28). doi: 10.1200/JCO.23.00775